Therefore, our study may also provide a novel mechanism for targeting Wnt/β-catenin signaling to promote antitumor immunity by overcoming cDC1 dysfunction in TME, suggesting that targeting BCL9/BCL9L to improve NF-κB-dependent antigen presentation in tumors is a potential approach to cancer therapy. The gene discussed is BCL9; the disease is cancer.